NL-OMON31682尚未招募不适用
Genetic and Radiological Screening of First Degree Family Members of Patients with Familial Liver Adenomatosis - Familial Liver Adenomatosis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Patients diagnosed with liver adenomatosis by histology or imaging studies
- •2. First line family members of 1.
- •2. Minimal age 18 years old
- •3. Informed consent must be obtained
排除标准
- •1. Patients under 18 years of age
- •2. Patients who are pregnant
- •3. Patients who are claustrofobic (MRI)
- •4. Patients who have magnetic or radiofrequency sensitive implants (MRI)
- •5. Patients with extreme obesity (MRI+US)
研究者
相似试验
尚未招募
不适用
Genetic Newborn Screening for Rare Diseases within the Screen4Care Projectgenetic newborn screeningDRKS00033501niversitätsklinikum Freiburg; Klinik für Neuropädiatrie und Muskelerkrankungen20,000
招募中
不适用
Genetic screening of an at-risk population for Hereditary TransthyRetin-related AMyloidosis and longitudinal monitoring of TTR positive subjectsCardiomyopathyAmyloidosisDRKS00016158Centogene AG Rostock5,000
已完成
不适用
Evaluation of Chromosomal Genetic Abnormalities in Cells in Urine Using UroVysioBladder cancerJPRN-UMIN000015194roVysion Domestic Japanese Clinical Performance Trial Steering Committee450
进行中（未招募）
1 期
Biomarkers of Response to Pembrolizumab Combined with Chemotherapy in Non-Small Cell Lung Cancer (Keynote-782)EUCTR2018-002598-22-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
进行中（未招募）
1 期
Biomarkers of Response to Pembrolizumab Combined with Chemotherapy in Non-Small Cell Lung Cancer (Keynote-782)EUCTR2018-002598-22-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100